
| 2020 | |
|---|---|
| Criterium: | Position: |
| Overall Score: | 22 |
| Total Project Funding per Partner: | 4 |
| Total Number of Projects: | > 1000 |
| 2019 | |
| Criterium: | Position: |
| Overall Score: | 90 |
| Total Project Funding per Partner: | 28 |
| Total Number of Projects: | > 1000 |
Total number of projects: 3
As coordinator: 0
As participant: 0
Sole participant: 3
Coordinator / Participant Ratio: *
| Total project funding [€]: | Projects [No]: | |||||
|---|---|---|---|---|---|---|
| Year: | coordinator* | participant* | per partner | as coordinator | as participant | |
| 2022 | 35.000.000 | 0 | 35.000.000 | 1 | ||
| 2020 | 100.000.000 | 0 | 100.000.000 | 1 | ||
| 2019 | 36.000.000 | 0 | 36.000.000 | 1 | ||
| Institution: | Projects [No]: |
|---|
Total number of partners: 0
Partner loyalty:
Frequent Partner: (> 2 projects): 0
Rare Partner: 0
Frequent / Rare Partner Ratio: 0
| Start date | Project | acronym | role | funding | partners |
|---|---|---|---|---|---|
| 2022-08-01 | Clinical development of Rift Valley fever vaccines in endemic regions | RIFTVAX | coordinator | 35.000.000 | 1 |
| 2020-07-24 | PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19 | COVID-19 VACCINES | coordinator | 100.000.000 | 1 |
| 2019-01-01 | Developing a diverse portfolio of vaccine candidates for Rift Valley Fever, Chikungunya and Ebola | ECRC | coordinator | 36.000.000 | 1 |